In vitro activities of fleroxacin, cefetamet, ciprofloxacin, ceftriaxone, trimethoprim-sulfamethoxazole, and amoxicillin-clavulanic acid against rare members of the family Enterobacteriaceae primarily of human (clinical) origin.

Antimicrobial Agents and Chemotherapy
P HohlM Altwegg

Abstract

Fleroxacin and cefetamet were evaluated in vitro against 38 infrequently encountered species (250 strains) of the family Enterobacteriaceae and compared with four established compounds. For all the strains tested, the fleroxacin MIC was less than or equal to 0.5 mg/liter, and for 98% of strains the cefetamet MIC was less than or equal to 8 mg/liter; even though the two new compounds did not quite reach the activities (on a weight-by-weight basis) of ciprofloxacin and ceftriaxone, respectively, they nonetheless clearly surpassed trimethoprim-sulfamethaxazole and amoxicillin-clavulanic acid. The very potent new oral compounds tested in this study appear to be promising for the treatment of clinically relevant infections due to uncommon species of Enterobacteriaceae.

References

Jun 1, 1989·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·P AngehrnR L Then
Oct 1, 1988·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·P GoubauM Boogaerts
Jun 1, 1988·Journal of Clinical Microbiology·H Chmel
Jul 1, 1988·Journal of Clinical Microbiology·R Zbinden, R Blass
Dec 1, 1987·Journal of Clinical Microbiology·T U Westblom, M E Coggins
Mar 1, 1987·Journal of Clinical Microbiology·S KrajdenJ L Penner
Jun 1, 1987·Journal of Clinical Microbiology·V K Wong
Aug 1, 1987·Journal of Clinical Microbiology·H W HorowitzG P Wormser
Aug 1, 1985·Journal of Clinical Microbiology·F D PienJ J Farmer
Jan 1, 1986·Archives of Internal Medicine·F D Pien, A E Bruce
Jun 1, 1984·Journal of Clinical Microbiology·J A BrouillardA Compere
Jul 1, 1984·Infection·P A ParmentB Palmer
Dec 1, 1984·Southern Medical Journal·K R DyeJ L Brockert
Dec 1, 1983·Southern Medical Journal·F D Pien, J J Farmer
Jul 1, 1983·The Journal of Urology·B H Bae, S B Sureka

❮ Previous
Next ❯

Citations

Dec 1, 1991·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·C BolletP de Micco
Nov 18, 2006·Canadian Journal of Microbiology·Hua YangXiuping Jiang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.